for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Curis, Inc.

CRIS.OQ

Latest Trade

2.52USD

Change

0.07(+2.86%)

Volume

41,907

Today's Range

2.45

 - 

2.55

52 Week Range

0.60

 - 

2.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.45
Open
2.50
Volume
41,907
3M AVG Volume
4.08
Today's High
2.55
Today's Low
2.45
52 Week High
2.90
52 Week Low
0.60
Shares Out (MIL)
33.20
Market Cap (MIL)
81.35
Forward P/E
--
Dividend (Yield %)
--

Next Event

Curis Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Curis Announces Promotion Of Bill Steinkrauss To Chief Financial Officer

Curis Reports Second Quarter 2019 Loss Per Share Of $0.22

Curis Reports Q1 Loss Per Share $0.30

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Curis, Inc.

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.

Industry

Biotechnology & Drugs

Contact Info

4 Maguire Rd

+1.617.5036500

http://www.curis.com/

Executive Leadership

James R. McNab

Independent Chairman of the Board

James E. Dentzer

President, Chief Executive Officer, Director

William E. Steinkrauss

Chief Financial Officer

Robert E. Martell

Head - Research and Development

Lori A. Kunkel

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
8.60
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-73.32
Return on Equity (TTM)
-59.67

Latest News

BRIEF-Curis Files For Mixed Shelf Of Upto $200 Mln

* CURIS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING Source text: (https://bit.ly/2rkihf5) Further company coverage:

BRIEF-Curis Reports Q1 Loss Per Share $0.07

* Q1 EARNINGS PER SHARE VIEW $-0.09 -- THOMSON REUTERS I/B/E/S

BRIEF-Curis Q4 Loss Per Share $0.05

* CURIS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-Curis announces pricing of public offering of common stock

* Curis Inc - pricing of an underwritten public offering of 20 million shares of its common stock Source text for Eikon: Further company coverage:

BRIEF-Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017

* Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017

BRIEF-Curis reports Q2 loss per share $0.10

* Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Curis Q1 loss per share $0.11

* Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S

BRIEF-Curis Q4 loss per share $0.08

* Curis reports fourth quarter and year-end 2016 financial results

BRIEF-Curis Inc exercised its option to extend exclusivity period with Aurigene

* Curis Inc - exercised its option to extend exclusivity period with Aurigene Source text for Eikon: Further company coverage:

BRIEF-Curis says announces full approval of Roche's Erivedge in European Union

* Says announces full approval of Roche's Erivedge in European Union

BRIEF-Curis reports appointment of Lori Kunkel to board of directors

* Curis announces appointment of Lori A. Kunkel, m.d. to board of directors Source text for Eikon: Further company coverage:

BRIEF-Curis Q3 loss per share $0.21

* Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up